Ana H.C. Guimarães

A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement

George Dangas, Jan G.P. Tijssen, Jochen Wöhrle et al. · New England Journal of Medicine · 2019 · 526 citations · Full text

Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement

Ole De Backer, George Dangas, Hasan Jilaihawi et al. · New England Journal of Medicine · 2019 · 272 citations · Full text

High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke

Frank W.G. Leebeek, M.P.J. van Goor, Ana H.C. Guimarães et al. · Journal of Thrombosis and Haemostasis · 2005 · 107 citations

Cerebrovascular Disease, Thrombosis, Hematology +17

Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study

Stephan Windecker, Jan G.P. Tijssen, Gennaro Giustino et al. · American Heart Journal · 2016 · 103 citations · Full text

Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests

D.C. Rijken, Edith L. Kock, Ana H.C. Guimarães et al. · Journal of Thrombosis and Haemostasis · 2012 · 88 citations · Full text

Thrombosis, Hepatology, Liver Physiology +8